Literature DB >> 19525223

Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1).

Capucine Van Rechem1, Brian R Rood, Majid Touka, Sébastien Pinte, Mathias Jenal, Cateline Guérardel, Keri Ramsey, Didier Monté, Agnès Bégue, Mario P Tschan, Dietrich A Stephan, Dominique Leprince.   

Abstract

The tumor suppressor gene HIC1 (Hypermethylated in Cancer 1) that is epigenetically silenced in many human tumors and is essential for mammalian development encodes a sequence-specific transcriptional repressor. The few genes that have been reported to be directly regulated by HIC1 include ATOH1, FGFBP1, SIRT1, and E2F1. HIC1 is thus involved in the complex regulatory loops modulating p53-dependent and E2F1-dependent cell survival and stress responses. We performed genome-wide expression profiling analyses to identify new HIC1 target genes, using HIC1-deficient U2OS human osteosarcoma cells infected with adenoviruses expressing either HIC1 or GFP as a negative control. These studies identified several putative direct target genes, including CXCR7, a G-protein-coupled receptor recently identified as a scavenger receptor for the chemokine SDF-1/CXCL12. CXCR7 is highly expressed in human breast, lung, and prostate cancers. Using quantitative reverse transcription-PCR analyses, we demonstrated that CXCR7 was repressed in U2OS cells overexpressing HIC1. Inversely, inactivation of endogenous HIC1 by RNA interference in normal human WI38 fibroblasts results in up-regulation of CXCR7 and SIRT1. In silico analyses followed by deletion studies and luciferase reporter assays identified a functional and phylogenetically conserved HIC1-responsive element in the human CXCR7 promoter. Moreover, chromatin immunoprecipitation (ChIP) and ChIP upon ChIP experiments demonstrated that endogenous HIC1 proteins are bound together with the C-terminal binding protein corepressor to the CXCR7 and SIRT1 promoters in WI38 cells. Taken together, our results implicate the tumor suppressor HIC1 in the transcriptional regulation of the chemokine receptor CXCR7, a key player in the promotion of tumorigenesis in a wide variety of cell types.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525223      PMCID: PMC2742858          DOI: 10.1074/jbc.M109.022350

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.

Authors:  S Deltour; C Guerardel; D Leprince
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.

Authors:  Emma Langley; Mark Pearson; Mario Faretta; Uta-Maria Bauer; Roy A Frye; Saverio Minucci; Pier Giuseppe Pelicci; Tony Kouzarides
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

3.  Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53.

Authors:  C Guerardel; S Deltour; S Pinte; D Monte; A Begue; A K Godwin; D Leprince
Journal:  J Biol Chem       Date:  2000-11-09       Impact factor: 5.157

4.  hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.

Authors:  H Vaziri; S K Dessain; E Ng Eaton; S I Imai; R A Frye; T K Pandita; L Guarente; R A Weinberg
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

5.  Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors.

Authors:  Wen Yong Chen; Xiaobei Zeng; Mark G Carter; Craig N Morrell; Ray-Whay Chiu Yen; Manel Esteller; D Neil Watkins; James G Herman; Joseph L Mankowski; Stephen B Baylin
Journal:  Nat Genet       Date:  2003-01-21       Impact factor: 38.330

6.  Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1.

Authors:  Sébastien Pinte; Cateline Guérardel; Sophie Deltour-Balerdi; Andrew K Godwin; Dominique Leprince
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

7.  Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma.

Authors:  Brian R Rood; Huizhen Zhang; David M Weitman; Philip H Cogen
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

8.  The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif.

Authors:  Sophie Deltour; Sébastien Pinte; Cateline Guerardel; Bohdan Wasylyk; Dominique Leprince
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

9.  Involvement of Rel/nuclear factor-kappaB transcription factors in keratinocyte senescence.

Authors:  David Bernard; Karo Gosselin; Didier Monte; Chantal Vercamer; Fatima Bouali; Albin Pourtier; Bernard Vandenbunder; Corinne Abbadie
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

10.  Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control.

Authors:  B Zhang; K J Chambers; D Leprince; D V Faller; S Wang
Journal:  Oncogene       Date:  2008-11-17       Impact factor: 9.867

View more
  35 in total

1.  Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells.

Authors:  Capucine Van Rechem; Gaylor Boulay; Sébastien Pinte; Nicolas Stankovic-Valentin; Cateline Guérardel; Dominique Leprince
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

2.  Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins.

Authors:  Gaylor Boulay; Marion Dubuissez; Capucine Van Rechem; Antoine Forget; Kristian Helin; Olivier Ayrault; Dominique Leprince
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

Review 3.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

4.  The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Authors:  Bénédicte Foveau; Gaylor Boulay; Sébastien Pinte; Capucine Van Rechem; Brian R Rood; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

5.  C-X-C motif receptor 7 in gastrointestinal cancer.

Authors:  Hwan-Jung Yun; Hyewon Ryu; Yoon Seok Choi; Ik-Chan Song; Deog-Yeon Jo; Samyong Kim; Hyo Jin Lee
Journal:  Oncol Lett       Date:  2015-06-22       Impact factor: 2.967

6.  Loss of Hypermethylated in Cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through β-2 adrenergic receptor (ADRB2) misregulation.

Authors:  Gaylor Boulay; Nicolas Malaquin; Ingrid Loison; Bénédicte Foveau; Capucine Van Rechem; Brian R Rood; Albin Pourtier; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

Review 7.  Mammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism.

Authors:  Caleb C Lord; Gwynneth Thomas; J Mark Brown
Journal:  Biochim Biophys Acta       Date:  2013-01-14

8.  HIC1 modulates uveal melanoma progression by activating lncRNA-numb.

Authors:  Guangcun Cheng; Jie He; Leilei Zhang; Shengfang Ge; He Zhang; Xianqun Fan
Journal:  Tumour Biol       Date:  2016-07-23

Review 9.  In vivo metabolite profiling as a means to identify uncharacterized lipase function: recent success stories within the alpha beta hydrolase domain (ABHD) enzyme family.

Authors:  Gwynneth Thomas; Amanda L Brown; J Mark Brown
Journal:  Biochim Biophys Acta       Date:  2014-01-12

Review 10.  Chemokines and chemokine receptors as promoters of prostate cancer growth and progression.

Authors:  Nicole Salazar; Miguel Castellan; Samir S Shirodkar; Bal L Lokeshwar
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2013       Impact factor: 1.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.